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R198monoamines disrupts the ability of
flies to track the odor plume, while a
rescue of octopamine signaling in
these flies is sufficient to restore normal
tracking.
These experiments suggest that
the cross-modal odor modulation of
visual motion responses is driven
specifically by octopamine release
onto higher-order motion sensitive
neurons, rather than by modulation
of input pathways such as T4/T5
neurons. Yet given prior work
also implicating octopamine as a
modulator of the gain of HS neurons,
why does odor not lead to an increase
in the response of HS neurons as
seen in Hx (Figure 1B)? One possibility
is that octopamine neurons act via
more than one postsynaptic receptor
pathway, differentially expressed
in higher order neurons. While
experimental exogenous application
of octopamine might induce
modulation of gain in HS neurons also,
the odor-mediated release of
endogenous octopamine might not be
agonistic for all post-synaptic targets.
Indeed, this difference between the
response of Hx and Hs provides an
exciting opportunity for a broader
investigation of the subtle ways inwhich aminergic signaling might be
involved in differential cross-modal
interactions within the insect nervous
system.
Regardless of the outcome of
future work to reconcile these
findings, the study by Wasserman
et al. [1] provides clear evidence for
a mechanism that dynamically
enhances sensory perception in a
contextually appropriate manner. In
humans, congruent odor cues have
been shown to facilitate perception of
color or shape based visual cues,
just as the inventors of Smell-O-Vision
had hoped to exploit in their 1950s
experiments in multisensory cinema.
Until recently, however, no similar
effect was known for motion,
which is primarily processed in the
visual dorsal stream, a subdivision
of the cortex that shares many
properties in common with the fly
lobula plate [8]. Another recent
study, however [9], showed that
olfaction can indeed bias visual
motion perception in humans.
It remains to be seen whether such
cross-modal interactions in the
human dorsal stream also involve
aminergic modulation, as now shown
in the fly.References
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My Dying FriendsApoptosis is an essential form of cell death underlying daily tissue
regeneration. In tumor biology, apoptosis resistance is a well-established
hallmark of cancer that is targeted by therapeutic approaches. A new study
assigns a hitherto-underestimated function to this ‘deadly friend’: apoptotic
cells promote tumor growth, accumulation of tumor-associated macrophages,
and angiogenesis.Kirsten Lauber1,*
and Martin Herrmann2
Being a central opponent of cell
proliferation, apoptosis plays a pivotal
role in tissue homeostasis. Apoptotic
cells are swiftly removed by
phagocytes and stimulate wound-
healing responses, along with the
production of anti-inflammatory
cytokines [1]. In situ, apoptotic cells
are commonly associated with
macrophages, which have a
tissue-remodeling, angiogenesis-
promoting phenotype that is alsoknown of tumor-associated
macrophages (TAMs). Accumulation of
TAMs has been reported to correlate
with poor prognosis in various human
malignancies, and the contribution
of TAMs to cancer progression has
been extensively explored [2]. The
mechanisms orchestrating the
accumulation, differentiation and
polarization of TAMs are still poorly
understood, but the association of
intra-tumoral apoptosis, TAM
accumulation, and disease
aggressiveness suggests a
functional interconnection [3].In a new study in this issue ofCurrent
Biology, Ford et al. [4] examine the
impact of apoptosis on tumor cell
proliferation and tumor growth in
transplantation models of lymphoma
andmelanoma. They report that human
Burkitt lymphoma cells overexpressing
the anti-apoptotic proteins Bcl-2 or
Bcl-xL showed significantly delayed
tumor growth compared with their
wild-type counterparts after
transplantation into immunodeficient
SCID mice. Tumor cell proliferation
in vivo was strongly impaired,
although basal apoptosis was
reduced and proliferation in vitro
was increased. These rather surprising
observations suggest that inhibition
of spontaneous apoptosis interferes
with non-tumor cell autonomous
mechanisms that favor tumor
growth in vivo. Transplantation
experiments with the l-Myc
lymphoma model further strengthen
this conclusion: depletion of apoptotic
cells from the inoculum strongly
attenuated tumor growth, whereas
Figure 1. Apoptosis-driven tumor progression.
In wild-type lymphoma (left), spontaneously apoptosing tumor cells are engulfed by macro-
phages, thus polarizing them into TAMs. Lymphoma TAMs exhibit an efferocytic, pro-angio-
genic, matrix-remodeling, and wound-healing phenotype, which contributes to accelerated
tumor progression. In Bcl-2-expressing lymphoma (right), spontaneous apoptosis is strongly
reduced: fewer TAMs are observed, tumors have a lower vessel density, and tumor progres-
sion is impaired.
Dispatch
R199admixing of apoptotic cells greatly
accelerated it.
Histologically, Bcl-2-overexpressing
lymphomas displayed lower vessel
density and increased HIF-1a levels,
indicating that these tumors were
more hypoxic than the wild-type
controls [4]. The authors focused
their attention on TAMs, given that
they are crucial players in apoptotic
cell clearance (efferocytosis), wound
healing, and angiogenesis. In biopsies
from human Burkitt’s lymphoma,
they observed a close correlation
between the frequencies of apoptotic
cells and TAMs. This was further
corroborated in their xenograft model,
where Bcl-2- or Bcl-xL-overexpressing
lymphomas revealed significantly
decreased numbers of TAMs
correlating with reduced intra-tumoral
apoptosis. Interestingly, attempts
to deplete lymphoma TAMs by
clodronate liposomes, which
effectively ablate circulating
monocytes, indicated that these
TAMs did not derive from recruited
circulating monocytes, but
originated — at least in part — from
macrophage proliferation in situ.
Lymphoma TAMs adopted an
efferocytic, pro-angiogenic, and
tissue-remodeling phenotype as
determined by transcriptomic profiling
of laser microdissected TAMs. This
distinct state of activation had
presumably been ‘instructed’ by
apoptotic lymphoma cells, as observed
in in vitro co-incubation assays. It was
clearly different from the activation
state of isolated tingible body
macrophages — germinal center
macrophages that have phagocytosed
apoptotic B cells — suggesting that
apoptotic malignant B cells promote
the formation of a different
macrophage phenotype than that
promoted by apoptotic germinal center
B cells. The lymphoma TAMs had
features in common with ‘alternatively
activated’ macrophages, including
high expression of CD206 [5], but also
displayed essential differences, for
instance the lack of arginase or
vascular endothelial growth factor
expression. Similar findings have been
reported for TAMs in murine mammary
tumors [6]. Since interleukin-4 (IL-4) is
a key cytokine that drives the
differentiation of alternatively activated
macrophages, Ford et al. [4] addressed
the impact of IL-4Ra signaling on tumor
growth in transplanted l-Myc
lymphomas. When grafted ontoIL-4Ra-deficient mice, lymphomas
grew with delayed kinetics, an effect
that was even more pronounced when
apoptotic tumor cells were depleted
from the inoculum. Nevertheless,
expression of crucial TAM markers
was only marginally affected in mice
lacking IL-4Ra. The authors conclude
that apoptotic cells and host IL-4Ra
signaling both support tumor growth,
but via independent mechanisms.
This study provides an impressive
amount of data supporting the notion
that apoptotic tumor cells promote
the growth of transplanted tumors.
A similar enhancement of tumor
progression by inoculation with a
mixture of viable and irradiated
tumor cells was reported over
50 years ago [7] and also recently
in an allogeneic melanoma
transplantation model [8].
Furthermore, Ford et al. [4] present
convincing correlation analyses of
intra-tumoral apoptosis, TAM
accumulation, and angiogenesis
(Figure 1). This is in line with
observations from various human
malignancies, where the correlation
between TAM density and poor
prognosis is well acknowledged,
and mechanistic evidence from
preclinical studies that has
established the crucial role of TAMs in
cancer progression [2].Most intriguing and largely
provocative is the causal link between
tumor cell apoptosis, increased TAM
accumulation, and subsequent cancer
progression. This raises several
interesting questions. How can
apoptotic cells support the
proliferation of viable cells, and which
signals are involved in apoptosis-
driven tumor growth? A huge repertoire
of biologically active molecules is
released during apoptosis, ranging
from nucleotides, lipids and proteins to
microvesicles. These mediators
orchestrate phagocyte recruitment and
stimulate efferocytosis, but they also
exert other pleiotropic effects [1,9].
Lactoferrin appears to be a promising
candidate for an apoptotic-cell-derived
trophic signal, since it can mediate
multiple effects on living and dying
tumor cells as well as on cells of the
tumormicroenvironment [10]; however,
its functional involvement remains to
be elucidated. Interestingly,
apoptosis-mediated compensatory
proliferation is only observed when
apoptotic and viable cells are
inoculated at the same site [8], implying
that the responsible soluble factors
display a rather limited operating range
or that direct cell–cell contact is
required.
The data presented by Ford et al. [4]
suggest that the apoptosis-driven
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R200promotion of tumor growth acts in a
non-tumor cell autonomous manner.
Apparently, accumulation and
polarization of TAMs are instigated,
but other cells within the tumor
microenvironment may also be
affected — for instance, endothelial
cells. The authors report that
apoptotic lymphoma cells and
apoptotic germinal center B cells shift
macrophage polarization in different
directions. This stimulates the
question of whether apoptotic
malignant and apoptotic non-
malignant cells differ per se, or
whether additional factors of the
tumor microenvironment are
important. Most tumors are exposed
to metabolically challenging
conditions, including hypoxia as well
as acidic pH, and lactate has recently
been attributed a key role in TAM
polarization in murine melanoma,
lung, and colon cancer [11]. Yet, the
TAM phenotype described in this
earlier work diverges from the
lymphoma TAM type reported by Ford
et al. [4]; the observed differences
presumably arise from the tumor
models employed.
Other groups have provided
evidence for tumor cell autonomous
mechanisms of apoptosis-driven
cancer progression, showing
that admixing of apoptotic cells
accelerated proliferation of cancer
cells in vitro [8,12]. Ford et al. [4]
instead observed a decreased
expansion of apoptosis-competent
lymphoma in vitro. This discrepancy
could stem from differences in the
ratios of apoptotic to cancer cells:
whereas basal apoptosis rates in
lymphoma cell populations ranged
from 5 to 10%, most admixing
experiments were performed with a
huge excess of apoptotic cells
(100–500 fold). Mechanistically,
prostaglandin E2 has previously
been attributed to drive tumor cell
proliferation induced by apoptotic
cells, and, from studies in lower
model organisms, an involvement of
Hedgehog signaling in apoptosis-
induced proliferation is known [12].
Further analyses are warranted to
characterize in detail the tumor cell
autonomous trophic factors derived
from apoptotic cells.
Ford et al. [4] utilized overexpression
of Bcl-2 and Bcl-xL to inhibit apoptosis.
However, apoptosis resistance is a
well-acknowledged hallmark of cancer,
and chromosomal amplification andoverexpression of anti-apoptotic Bcl-2
family members — often associated
with poor prognosis — have been
reported for various malignancies,
particularly lymphoma [13–15].
The solution to this conundrum may
be a question of timing. During
tumorigenesis, oncogenes like Myc
are activated and promote proliferation
but also cell death. Myc-induced cell
death can be blocked by anti-apoptotic
Bcl-2 family members, and their
overexpression is well known to
synergize with enforced Myc
expression in lymphomagenesis [16].
Accordingly, apoptosis resistance
appears to be beneficial for
establishing the malignant phenotype.
Later on, when the growing tumor
has to acquire the capacity to
organize nutrient and oxygen supply,
a certain percentage of apoptotic
tumor cells can obviously facilitate
TAM recruitment and angiogenesis.
Transplantation models cannot
evaluate this hypothesis, but genetic
cancer models with inducible Bcl-2
expression could dissect the kinetics
of Bcl-2 requirement in different phases
of tumorigenesis and tumor
progression.
The observations presented by Ford
et al. [4] complement other studies
showing that apoptosis-inducing
therapy stimulates tumor repopulation,
and macrophages have been
proposed to play a crucial role in this
scenario [12,17]. Conversely, Bcl-
2-targeting, pro-apoptotic cancer
therapy has proven to be effective in
preclinical models and is currently
undergoing clinical evaluation [18]. It
would be worth considering the
development of new therapeutic
modalities that stimulate tumor cell
death and simultaneously interfere
with apoptosis-driven tumor
repopulation. Shifting the mode of cell
death towards a more immunogenic
phenotype could be one approach [19].
To this end, caspase inhibition appears
to be a valuable tool, since it can
trigger necroptosis when applied
together with a death stimulus.
Nevertheless, the applicability of this
approach has to be carefully evaluated
because caspase inhibition could also
confer therapy resistance via overall
inhibition of cell death. Interfering with
the process of efferocytosis might be
an alternative strategy to break the
causal link between apoptosis and
tumor repopulation. Masking apoptotic
cells with annexin A5 has been shownto impair the efferocytic uptake of
apoptotic lymphoma cells [20].
However, whether this also translates
into repolarization of TAMs still
remains to be defined. Finally, the
apoptotic-cell-derived signals that
orchestrate accumulation and
polarization of TAMs could open new
therapeutic perspectives. In this
regard, the identification of
prostaglandin E2 reanimates the
discussion about cyclo-oxygenase
inhibition as an adjuvant to cancer
therapy.
In conclusion, promotion of tumor
growth by apoptotic cells, as
described by Chris Gregory’s group,
has been underestimated for a long
time. The generality of these findings
as well as the underlying molecular
details require further in-depth
clarification, but it is time to redefine
the traditional black-and-white
picture of cell death and cell
proliferation in tumor biology —
particularly when thinking of novel
anti-cancer therapies.References
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Their ImprintA recent study has revealed that loss of neuronal expression of the paternally
imprinted gene Ube3a in Angelman syndrome results in selective neuronal loss
of robust circadian oscillations, with a resulting behavioural phenotype, and
adipose tissue accumulation.David W. Ray
Life evolved on Earth under conditions
of marked environmental oscillation:
cyclical transitions from day to night.
Under these conditions complex life
apportioned specific activities to
particular phases, for example
photosynthesis during the light phase,
or sleep during the dark phase.
However, such adaptations were
driven by internal rhythms, rather than
being a mere reaction to the change in
environment; i.e., a biological clock. In
a recent study reported in this issue
of Current Biology from Shi et al. [1]
new insights have been gained into
how the biological clock is controlled,
and with what consequences for
behavior.
The molecular basis of the circadian
(circa; about, diem; day) clock has been
elucidated, and the current model is of
a transcriptional and translational
feedback loop. This now includesmany
different molecular components, some
of which are rhythmically expressed, or
modified, and which participate in
feedback loops to modulate one
another’s expression. The core circuit
involves an activating arm provided by
the bHLH-PAS transcription factor
BMAL1/ARNTL, which dimerises with
CLOCK, or NPAS2. The heterodimeric
transcription factor activatesexpression of components of the
repressive feedback arm of the clock,
namely, PERIOD and
CRYPTOCHROME.
A core requirement for the clock to
work is that at least one central clock
component shows a rhythmic change
in abundance of activity. Indeed, both
PERIOD and CRYPTOCHROME
proteins shows a rhythmic oscillation.
Ubiquitinylation of CRYPTOCHROME,
with resulting effects on protein
turnover and circadian period, has
been discovered to be due to the F-box
proteins Fbxl3 and Fbxl21. However,
it was not thought that BMAL1
oscillation was required for core clock
function, or that such a regulatory
pathway existed. However, a
ubiquitinylation pathway mediated
by Ube3a that regulates BMAL1
abundance and affects clock function
was revealed recently in vitro.
Ube3a is encoded on human
chromosome 15q11-q13. This is of
interest as deletions of the maternal
copy of chromosome 15 in this
region are causative for the
complex neurodevelopmental
disorder Angelman syndrome (AS).
AS is characterized by a
neurodevelopmental defect resulting
in motor impairments, learning
difficulties, epilepsy, and sleep
disorders [2,3]. There is no treatment,and management is targeted at
symptom control, with most patients
requiring medication to control
epilepsy. AS results from genomic
imprinting, as the paternal allele is
imprinted, and so not expressed.
Therefore, loss of the maternal allele
results in loss of Ube3a expression
in tissues affected by the imprinting.
In AS, paternal imprinting is only
seen in the brain, so loss of Ube3a
expression is seen only in brain
neurons, and not glia or peripheral
tissues [4]. These observations
suggest a fascinating mechanistic link
between loss of neuronal Ube3a
expression, leading to altered BMAL1
ubiquitinylation [5] and stability, and
circadian disruption, leading to sleep
disturbance, specifically short sleep
duration and increased sleep onset
latency.
In the study reported in this issue
Shi et al. [1] identify a causal link
between Ube3a expression and
circadian rhythm in mouse models
of AS. They report weakened
rhythms in vivo, which is manifest
by more rapid re-setting of the
circadian oscillation to changes in
environmental light timing, an
experimental model of jet lag or shift
work. Similarly, under constant light
conditions the AS model animals show
an accelerated decay in rhythmic
behavior.
Analyses of tissue ex vivo by Shi
et al. provided new insight into the
causative mechanisms of AS in their
model animals. While no detectable
differences in circadian oscillations in
peripheral tissues were seen in AS
animals compared to controls, the
central brain clock located in the
suprachiasmatic nucleus had a
